anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The proposed study is a single center, unblinded, non randomized, phase I/II trial in which the patients will be treated with a single dose of autologous stromal vascular cells (SVF) isolated from 500 ml of adipose tissue extracted from the infraumbilical area. The cellular product will be administered via intra-articular injection into patients with moderate to severe osteoarthritis (OA). Administration will be performed by injection into the synovial space. The dosing regimen will consist of two intraarticular injection of autologous SVF into the index knee. Total injection volume will be about 30 mL in two 15 mL aliquots via a 23 gauge needle inserted 1.5 cm. deep into the intraauricular space of the knee. The total number of SVF to be injected is 1.0 x 10(7) to 5 x 10(7).

The purpose of this study will be to define the safety and efficacy of SVF therapy in improving joint function and the quality of life in patients with OA of the knee. We plan to enroll twenty subjects for treatment for an adequate sample size for safety analysis with signals of efficacy. The primary safety outcome will be tabulation of adverse events related to treatment. Efficacy will be quantified at 3, 6 and 12 months by the total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).
Autism is a complex biological disorder that generally lasts throughout a person's life. It starts before age three and causes delays or problems with many different ways in which a person develops or grows. Some people with autism become very aggressive and can hurt others or themselves. This study will test the hypothesis that aggressive autistic adolescents will show a significantly greater response to valproate maintained at blood levels of 75-100 mcg/ml than to placebo. The study will also assess the safety of valproate in autistic adolescents. This represents the first double-blind study of valproate in mentally retarded/developmentally delayed populations.

Participants in this study will undergo DSM-IV evaluation, the Autism Diagnostic Interview-Revised and Autism Diagnostic Observation Schedule, and baseline blood tests. After baseline screening, all participants will be given a placebo for 1 week. Participants will then be randomized to receive either valproate or placebo for 8 weeks. Dosage adjustment according to blood levels drawn at the end of weeks 2 and 4 will be arranged with parents by a child psychiatrist without breaking the blind. The Aberrant Behavior Check-list-Community (ABC-C) irritability subscale will be the primary measure; the Overt Aggression Scale (OAS), ABC-C hyperactivity subscale, Clinical Global Impressions (CGI) problem severity, Self-Injurious Behavior Questionnaire (SIB-Q), and a valproate side effects checklist will be secondary measures.
Coronary artery disease (CAD) is the leading cause of death in industrialized countries. Current therapies for restoration of coronary flow are percutaneous coronary intervention (PCI) or surgical revascularization. However, inherent to them are procedure-related risks and the fact that CAD progression is not prevented. Additionally, up to one fourth of all CAD patients are not amenable to standard revascularization therapies. Thus, there is a need for alternative therapies. Coronary collaterals as natural bypasses are anastomoses without an intervening capillary bed between portions of the same coronary artery or between different coronary arteries. The coronary collateral circulation is prevalent in humans and in CAD the amount of collateral flow is directly related to infarct size, all-cause- and cardiac mortality. Thus, the goal is to promote collateral function in the sense of prophylactic myocardial salvage.

Coronary (collateral) blood flow occurs almost entirely during diastole. Fluid shear stress (FSS) is the driving force in the formation, promotion and maintenance of collaterals (i.e. arteriogenesis). It is the product of blood viscosity and shear rate, the latter being the fluid velocity change between different fluid layers which is related to the fluid velocity at the endothelium. Prolongation of diastole via reduction of resting heart rate (RHR) is naturally equal to extension of shear stress at the endothelium. Bradycardia is likely to be the key factor for augmented collateral function: In several animal models, an inverse relation between heart rate and collateral function was found. We have recently confirmed this finding investigating collateral function measurements in normal coronary arteries of our patient population.

The fact that beta blockers depress contractility and unmask beta-adrenergic coronary vasoconstriction has prompted the development of selective I(f)-inhibitors. To date, ivabradine is the only clinically available specific inhibitor of the pacemaker current in the sinuatrial node (called "funny" current, because of permeability for mixed ions and activation by hyperpolarization instead of depolarization, I(f)). It acts as a pure heart rate lowering agent without affecting blood pressure, myocardial contractility, intra-cardiac conduction, or ventricular repolarization. In contrast to beta blockers or calcium channel blockers, it mimics physiological bradycardia and is therefore appropriate for the purpose of this study. By bradycardization in CAD, ischemia is targeted via reduction of myocardial oxygen demand and increase of oxygen supply without negative inotropic, coronary vasoconstrictive, or metabolic effects. In terms of anti-anginal efficacy, ivabradine has been found to be as effective as atenolol or amlodipine.
The invention discloses a compound preparation for treating dairy cow mammitis. The compound preparation is prepared from, by weight, 1 part of lavender essential oil, 1-2 parts of cinnamon essential oil, 1-3 parts of wild marjoram essential oil and 3-6 parts of auxiliary materials. A preparation method of the compound preparation is provided. The compound preparation and the preparation method have the advantages that the plant essential oil is adopted as effective ingredients, the good effects of clearing away heat and toxic materials, resisting bacteria and diminishing inflammation are achieved, the effect of treating dairy cow mammitis is extremely good, and due to the adoption of the pure traditional Chinese medicine preparation and no chemical drug ingredient is contained, the safety of dairy products is facilitated. Uniform solids are obtained through stirring, stable performance and controllable quality are achieved, and industrial production is well facilitated. The compound preparation serves as traditional Chinese medicine, the effect of the compound preparation is definite, no residue or toxic or side effect is generated, the compound preparation can be used in a lactation period and can become good substitute goods of antibiotics, and the obtained traditional Chinese medicine compound ointment has high application value in veterinary clinical medicine.
Adult Patients with Type 1 Diabetes

In two clinical studies (Studies A and B), adult patients with type 1 diabetes (Study A, n=585, Study B n=534) were randomized to 28 weeks of basal-bolus treatment with Insulin Glargine or NPH insulin. Regular human insulin was administered before each meal. Insulin Glargine was administered at bedtime. NPH insulin was administered either as once daily at bedtime or in the morning and at bedtime when used twice daily.

In Study A, the average age was 39 years. The majority of patients were White (99%) and 56% were male. The mean BMI was approximately 24.9 kg/m2. The mean duration of diabetes was 16 years.

In Study B, the average age was 39 years. The majority of patients were White (95%) and 51% were male. The mean BMI was approximately 25.8 kg/m2. The mean duration of diabetes was 17 years.

In another clinical study (Study C), patients with type 1 diabetes (n=619) were randomized to 16 weeks of basal-bolus treatment with Insulin Glargine or NPH insulin. Insulin lispro was used before each meal. Insulin Glargine was administered once daily at bedtime and NPH insulin was administered once or twice daily. The average age was 39 years. The majority of patients were White (97%) and 51% were male. The mean BMI was approximately 25.6 kg/m2. The mean duration of diabetes was 19 years.

In these 3 adult studies, Insulin Glargine and NPH insulin had similar effects on HbA1c (Table 9) with a similar overall rate of severe symptomatic hypoglycemia [see Adverse Reactions (6.1)].

Pediatric Patients with Type 1 Diabetes

In a randomized, controlled clinical study (Study D), pediatric patients (age range 6 to 15 years) with type 1 diabetes (n=349) were treated for 28 weeks with a basal-bolus insulin regimen where regular human insulin was used before each meal. Insulin Glargine was administered once daily at bedtime and NPH insulin was administered once or twice daily. The average age was 11.7 years. The majority of patients were White (97%) and 52% were male. The mean BMI was approximately 18.9 kg/m2. The mean duration of diabetes was 5 years. Similar effects on HbA1c (Table 10) were observed in both treatment groups [see Adverse Reactions (6.1)].
Urinary cytology will be collected using a Ch.14 bladder catheter after the removal of the cystoscope. Catheter will be placed at the bladder neck level.
The invention relates to the disclosure of the strong anti-angiogenetic activity of the pyrroloquinazoline in different in vitro and in vivo systems. Its activity is due to the antagonistic properties of the thrombin inhibitor PAR-1. This explains the preponderant role of the thrombin in activating the angiogenesis process and cancer progress. This discovery provides the possibility of developing new prototypes of anti-angiogenetic factors antagonistically bound to the inhibitor PAR-1. The (N3-cyclopropyl-7-(4-isopropyl-benzyl)-7H-pyrrolo[3,2-f]kinazolin-1,3-diamine) is the prototype substance of this new arrays of anti-angiogenetic factors. Since the development and metastasis of malignant tumours presupposes the generation of new vessels, the pyrroloquinazoline may be applied for the clinical therapy of cancer or other diseases such as chronic arthritis, psoriasis, diabetic retinitis etc, where the irregular angiogenesis plays a pathogenic role.
The purpose of the present invention is to establish methods for: building medical big data taking privacy into consideration; deriving a more appropriate medicine dosage corresponding to medicine dosage and attribute information of patients; and discovering, in addition to the effect of the medicine on one disease symptom, the effect on another disease symptom. In the present invention, a data collection unit  40  collects health examination data and the like. A patient attribute information acquisition unit  61  acquires at least one attribute of a patient input from a patient terminal  1 . A corresponding information acquisition unit  62  acquires, from a corresponding information database  82 , corresponding information indicating a correspondence relationship between a medicine dosage having an effect on a disease symptom of which the patient is aware and the at least one attribute. An optimal dosage calculation unit  63  calculates the optimal medicine dosage in respect to the disease symptom of which the patient is aware, on the basis of the patient attribute information and the corresponding information. A separate effect analysis unit  72  analyzes, on the basis of information other than the patient attribute information, an effect separate from an effect analyzed by an effect analysis unit  44.
Systems and methods for sealing a plurality of reservoirs of a microchip element with a sealing grid are provided. For example, in one embodiment, a microchip element comprises a primary substrate having a plurality of reservoirs defined therein. The microchip element also includes a single continuous sealing groove defined in the primary substrate that extends around each of the plurality of reservoirs. In addition, the microchip element includes a sealing substrate comprising a single continuous sealing protrusion extending therefrom. The single continuous sealing protrusion corresponds to and is configured to mate with the single continuous sealing groove to form a hermetic bond between the primary substrate and the sealing substrate. In this manner, the single continuous sealing groove and the single continuous sealing protrusion form a sealing grid about the plurality of reservoirs.
PURPOSE:To obtain a lignin glycoside which can satisfactorily be used as a medicine having anticancer action, wherein lignin and a polysaccharide are bonded in a specified bonding ratio, the polysaccharide is composed of uronic acid and a neutral saccharide, and the molecular weight lies in a specified range. CONSTITUTION:A lignin glycoside having the following properties: (i) lignin and a polysaccharide are bonded, (ii) the molecular weight is 60000-140000, (iii) the bonding ratio between the lignin and the polysaccharide is 1:1-20:1 (in terms of a molecular ratio), and (iv) the polysaccharide is composed of 60-70% uronic acid and 30-40% neutral saccharide. The lignin glycoside is prepared in the following way. Examples of the starting materials include tea, lithospermi radix, sophorae subprostratae radix, radix ginseng, pinecones and pine needles. The starting material is treated with a solvent such as hot water or ethanol and extracted with an alkaline solution. The pH of the extract is adjusted to 4-6. Ethanol is added to it, and the precipitated fraction is recovered. This fraction is purified by gel filtration, and the active portion is recovered. The lignin glycoside thus obtained may be subjected to dialysis, centrifugation, lyophilization, etc.
STUDY OBJECTIVE: Rib fractures (RF) are common injuries. Multiple analgesia strategies are available for treatment of pain associated with RF. However, the optimal multimodal technique for pain management is not known. The primary aim of this review was to evaluate the status of evidence derived from randomized clinical trials (RCTs) on the effectiveness of pain management modalities for rib fracture pain. Other patient-centered outcomes were secondary objectives.
METHODS: Searches were conducted in MEDLINE, Embase, Scopus, and Cochrane Library. The screening process involved two phases, two researchers independently screened the title and abstract and subsequently screened full text. RCT data were extracted independently by two research team members. Consensus was achieved by comparison and discussion when needed. Risk of bias assessment was performed using the Cochrane Risk of Bias 2 tool.
RESULTS: A total of 1344 citations were identified. Title and abstract screening excluded 1128 citations, and full text review excluded 177 articles. A total of 32 RCTs were included in the full review. Multiple analgesia techniques and medications were identified and their effect on pain score and need for rescue opioid analgesia. None of the included studies were judged to have a high risk of bias, while only 10 studies were assessed as having a low risk of bias.
CONCLUSIONS: This systematic review found that studies are of low quality with diverse methodologies and outcomes. A reduction in pain scores was found for epidural analgesia when compared with other modalities. However, the low quality of the evidence necessitates cautious interpretation of this finding. PROSPERO registration: CRD42022376298 (Nov, 16, 2022).
Tramadol Hydrochloride Extended-Release contains tramadol, an opioid agonist of the morphine-type. Such drugs are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. 

Tramadol can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing Tramadol Hydrochloride Extended-Release in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. 

Tramadol Hydrochloride Extended-Release could be abused by crushing, chewing, snorting, or injecting the dissolved product. These practices will result in the uncontrolled delivery of the opioid and pose a significant risk to the abuser that could result in overdose and death [see WARNINGS AND PRECAUTIONS ( 5.13), DRUG ABUSE AND DEPENDENCE ( 9), and OVERDOSAGE ( 10)] . 

Concerns about abuse, addiction, and diversion should not prevent the proper management of pain. The development of addiction to opioid analgesics in properly managed patients with pain has been reported to be rare. However, data are not available to establish the true incidence of addiction in chronic pain patients. 

Healthcare professionals should contact their State Professional Licensing Board, or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.
The increasing prevalence of obesity, type 2 diabetes mellitus (T2DM), and gestational diabetes (GDM) among pregnant women has risen dramatically worldwide. The antihyperglycemic drug metformin is the most common drug for T2DM treatment in non-pregnant individuals; nevertheless, it is increasingly being used for diabetes-complicated pregnancies. Studies on the long-term metabolic effects of this drug in offspring remain scarce. This work aimed to determine the effect of metformin exposure during pregnancy and lactation on the offspring of a model of diet-induced maternal hyperglycemia. Cohorts of pregnant mice were fed a 46% fat diet (HFD) or a control standard diet (SD). A group of dams were exposed to metformin during pregnancy and lactation. After weaning, the offspring were fed SD for 8 weeks and then challenged with a 46% HFD after puberty for 12 weeks. Irrespective of the maternal diet, offspring of metformin-exposed mothers had a lower body weight and reduced inguinal white adipose tissue (iWAT) mass after HFD challenge. This was associated with increased expression of Pparg, Fabp4, Glut4, Srebp1, and Fasn in the iWAT during adulthood in the metabolically impaired dams exposed to metformin, suggesting increased adipogenesis and de novo lipogenesis. Increased expression of Fasn associated with decreased methylation levels at its promoter and proximal coding region in the iWAT was found. These results suggest that metformin modulates gene expression levels by epigenetic mechanisms in maternal metabolic-impaired conditions.
Oxadative air dye prepns are made contg. a cpd (I) where X is an electron-attracting grp. (esp. nitrile grp., 1-4C aliphatic acyl grp., 2-5 C alkoxycarbonyl grp. or a mono- or binuclear aromatic acyl grp). I is used as coupler in conjunction with known developers such as p-phenylene diamine derivs., diaminopyridines, etc., to give hair tints with good resistance to light and washing. In contrast to known couplers, cpds. (I) can be used to give yellow tints.
Seven women in cohort of a previous study were found to have shortened closure times (CADP-CT \< 61s) at time of enrollment. They all underwent genetic testing for a hypercoagulable state.
This is a prospective, single-arm, single-center clinical study evaluating the first-line treatment of DH or TH lymphoma with Selinexor combined with RCHOP. There are three stages: screening, treatment and follow-up period. The screening period was 28 days before the first dose. Treatment period: Enrolled subjects were treated with Selinexor in combination with RCHOP every 21 days for a maximum of 6 cycles until the efficacy of SD or PD, drug toxicity became intolerable, subject withdrawal of consent, death, or continuation of chemotherapy deemed unsuitable by the investigator. Lugano2014 criteria were used to evaluate the efficacy during treatment. Objective effective rate, safety and survival data were observed during the experiment. After stopping treatment or completing 6 cycles of treatment, subjects entered the follow-up period, during which imaging evaluation (enhanced CT at focal site is recommended) was performed at the following intervals: once every 3 months for 2 years, once every 6 months for 3-5 years, and once every 5 years until the end of the follow-up period.
PURPOSE OF REVIEW: To review corneal crosslinking for keratoconus and corneal ectasia, and recent developments in the field. This study will review the mechanism of crosslinking, clinical approaches, current results, and potential future innovations.
RECENT FINDINGS: Corneal crosslinking for keratoconus was first approved by U.S. FDA in 2016. Recent studies have confirmed the general long-term efficacy of the procedure in decreasing progression of keratoconus and corneal ectasia. New types of crosslinking protocols, such as transepithelial treatments, are under investigation. In addition, adjunctive procedures have been developed to improve corneal contour and visual function in these patients.
SUMMARY: Crosslinking has been found to be well tolerated and effective with the goal of decreasing progression of ectatic corneal diseases, keratoconus and corneal ectasia after refractive surgery. Studies have shown its long-term efficacy. New techniques of crosslinking and adjunctive procedures may further improve treatments and results.
The present invention relates to genes and genes clusters which are expressed in a tissue specific manner. For example, the invention relates to a group of genes encoding GPCR-like receptors that are involved in the function and activity of the immune system. These genes are organized into a discrete cluster at chromosomal location 1q22 (the “immune gene complex”) and span about 700 kb of DNA. The region closest to the centromere comprises genes that are expressed predominantly in the thymus, while the distal region comprises genes which are expressed predominantly in the bone marrow and other hematopoietic cells. Another cluster of GPCR genes is located at chromosomal band 11q24. These genes are expressed predominantly in pancreatic tissue, establishing this region of chromosome 11 as a unique gene complex involved in pancreatic function. A cluster of transmembrane and GPCR-type receptor genes is also located at chromosomal band 11q12.2. These genes are expressed predominantly in the spleen (hence, “spleen gene” cluster), as well as other tissues of the immune and reticuloendothelial system (RES), indicating that establishing this region of the chromosome is involved is spleen, lymphoid, and/or reticuloendothelial function. Finally, genes coding for membrane proteins have been identified which are expressed selectively in bone marrow, kidney, pancreas, and retina.